Nectar Social | $10,600,000 | (Jun 6, 2025)
Baobab | $13,702,071 | (Jun 6, 2025)
Signify Bio | $15,000,000 | (Jun 6, 2025)
Certified by Founder
Lodge
DiogenX
start up
France
- Marseille
- 11/05/2023
- Series A
- $30,056,125
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world.
Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits.
DiogenX is headquartered in Marseille, with labs in Nice (France).
- Industry Biotechnology
- Website https://diogenx.com/
- LinkedIn https://www.linkedin.com/company/diogenx/
Voltrac | $2,286,772 | (Jun 6, 2025)
Allay Therapeutics | $57,500,000 | (Jun 6, 2025)
Flank | $10,000,000 | (Jun 6, 2025)
Obvio | $22,000,000 | (Jun 5, 2025)
Filament Syfter | $4,800,000 | (Jun 5, 2025)
Vivrelle | $62,000,000 | (Jun 5, 2025)
Sema4.ai | $25,000,000 | (Jun 5, 2025)